Dr Reddy's/Nordic Bioscience's diabetes drug balaglitazone passes Phase III
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories and Nordic Bioscience's partial PPAR-gamma agonist balaglitazone met its primary endpoint in its first Phase III trial in patients with type 2 diabetes. The companies are currently in discussions with regulators and hope to eventually file the drug in both the EU and the US.